Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Jawed Fareed

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Procedures

Blood Coagulation Tests

Anatomy

Thrombosis

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Adiguzel Cafer; Iqbal Omer; Hoppensteadt Debra; Jeske Walter; Cunanan Josephine; Litinas Evangelos; He Zhu; Walenga Jeanine M; Fareed Jawed
Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide.
Erez Offer; Gotsch Francesca; Mazaki-Tovi Shali; Vaisbuch Edi; Kusanovic Juan Pedro; Kim Chong Jai; Chaiworapongsa Tinnakorn; Hoppensteadt Deborah; Fareed Jawed; Than Nandor G; Nhan-Chang Chia-Ling; Yeo Lami; Pacora Percy; Mazor Moshe; Hassan Sonia S; Mittal Pooja; Romero Roberto
Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death.
Li Boyangzi; Suwan Jiraporn; Martin Jeffrey G; Zhang Fuming; Zhang Zhenqing; Hoppensteadt Debra; Clark Melanie; Fareed Jawed; Linhardt Robert J
Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Jawed Fareed (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Adiguzel Cafer; Iqbal Omer; Hoppensteadt Debra; Jeske Walter; Cunanan Josephine; Litinas Evangelos; He Zhu; Walenga Jeanine M; Fareed Jawed
Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2009;15(5):501-11.
2009: Erez Offer; Gotsch Francesca; Mazaki-Tovi Shali; Vaisbuch Edi; Kusanovic Juan Pedro; Kim Chong Jai; Chaiworapongsa Tinnakorn; Hoppensteadt Deborah; Fareed Jawed; Than Nandor G; Nhan-Chang Chia-Ling; Yeo Lami; Pacora Percy; Mazor Moshe; Hassan Sonia S; Mittal Pooja; Romero Roberto
Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2009;22(8):672-87.
2009: Li Boyangzi; Suwan Jiraporn; Martin Jeffrey G; Zhang Fuming; Zhang Zhenqing; Hoppensteadt Debra; Clark Melanie; Fareed Jawed; Linhardt Robert J
Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins.
Biochemical pharmacology 2009;78(3):292-300.
2009: Viskov Christian; Bouley E; Hubert P; Martinez Celine; Herman F; Jeske Walter; Hoppensteadt Debra; Walenga Jeanine M; Fareed Jawed
Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2009;15(4):395-401.
2009: Kannan Meganathan; Saxena Renu; Adiguzel Cafer; Fareed Jawed
An update on the prevalence and characterization of H-PF4 antibodies in Asian-Indian patients.
Seminars in thrombosis and hemostasis 2009;35(3):337-43.
2009: Cella Giuseppe; Vianello Fabrizio; Cozzi Franco; Marotta Helga; Tona Francesco; Saggiorato Graziella; Iqbal Omer; Fareed Jawed
Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases.
The Journal of rheumatology 2009;36(4):760-7.
2009: Adiguzel Cafer; Bansal Vinod; Litinas Evangelos; Cunanan Josephine; Iqbal Omer; Nelson Kelly; Kannan Meganathan; Hoppensteadt Debra; Fareed Jawed
Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2009;15(2):145-51.
2009: Adiguzel Cafer; Jeske Walter P; Hoppensteadt Debra; Walenga Jeanine M; Bansal Vinod; Fareed Jawed
Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2009;15(2):137-44.
2009: Zhu He; Hoppensteadt Debra; Adiguzel Cafer; Bick Rodger L; Fareed Jawed
Comparison of immunogenic potentials of bovine thrombin preparations.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2009;15(1):41-9.
2009: Zhu He; Hoppensteadt Debra; Wahi Rakesh; Cunanan Josephine; Adiguzel Cafer; Bick Rodger L; Fareed Jawed
Reduced immunogenic potential of membrane filtered bovine thrombin preparations for hemostatic application.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2009;15(1):32-40.
2008: Erez Offer; Romero Roberto; Hoppensteadt Debra; Than Nandor Gabor; Fareed Jawed; Mazaki-Tovi Shali; Espinoza Jimmy; Chaiworapongsa Tinnakorn; Kim Sung-Su; Yoon Bo Hyun; Hassan Sonia S; Gotsch Francesca; Friel Lara; Vaisbuch Edi; Kusanovic Juan Pedro
Tissue factor and its natural inhibitor in pre-eclampsia and SGA.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2008;21(12):855-69.
2008: Heilmann Lothar; Schorch Martin; Hahn Thomas; Adasz Geza; Schilberz Karin; Adiguzel Cafer; Fareed Jawed
Pregnancy outcome in women with antiphospholipid antibodies: report on a retrospective study.
Seminars in thrombosis and hemostasis 2008;34(8):794-802.
2008: Erez Offer; Espinoza Jimmy; Chaiworapongsa Tinnakorn; Gotsch Francesca; Kusanovic Juan Pedro; Than Nandor Gabor; Mazaki-Tovi Shali; Vaisbuch Edi; Papp Zoltan; Yoon Bo Hyun; Han Yu Mi; Hoppensteadt Debra; Fareed Jawed; Hassan Sonia S; Romero Roberto
A link between a hemostatic disorder and preterm PROM: a role for tissue factor and tissue factor pathway inhibitor.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2008;21(10):732-44.
2008: Clark M; Hoppensteadt D; Walenga J; Myers L; Cunanan J; Jeske W; Adiguzel C; Iqbal O; Fareed J
Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
International angiology : a journal of the International Union of Angiology 2008;27(5):370-6.
2008: Fareed Jawed; Jeske Walter; Fareed Daniel; Clark Melaine; Wahi Rakesh; Adiguzel Cafer; Hoppensteadt Debra
Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2008;14(4):385-92.
2008: Hoppensteadt Debra; Fareed Jawed; Klein Allan L; Jasper Susan E; Apperson-Hansen Carolyn; Lieber Elizabeth A; Katz William E; Malouf Joseph F; Stoddard Marcus F; Pape Linda A;
Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation.
The American journal of cardiology 2008;102(7):842-6.
2008: Nien Jyh Kae; Romero Roberto; Hoppensteadt Debra; Erez Offer; Espinoza Jimmy; Soto Eleazar; Kusanovic Juan Pedro; Gotsch Francesca; Kim Chong Jai; Mittal Pooja; Fareed Jawed; Santolaya Joaquin; Chaiworapongsa Tinnakorn; Edwin Samuel; Pineles Beth; Hassan Sonia
Pyelonephritis during pregnancy: a cause for an acquired deficiency of protein Z.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2008;21(9):629-37.
2008: Hoppensteadt Debra A; Wahi Rakesh; Adiguzel Cafer; Iqbal Omer; Ramacciotti Eduardo; Bick Rodger L; Messmore Harry L; Bansal Vinod; Fareed Jawed
Contaminant in the recalled unfractionated heparin preparations: where is the problem?
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2008;14(3):261-6.
2008: Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
International angiology : a journal of the International Union of Angiology 2008;27(3):176-92.
2008: Terrab Abdel; Pawlak Dan; Spaay Pat; Hoppensteadt Debra; Fareed Jawed
Further removal of factor v related antigen from bovine thrombin by utilizing a membrane-filtration step.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2008;14(2):135-40.
2008: Jeske Walter P; Walenga Jeanine M; Hoppensteadt Debra A; Vandenberg Curtis; Brubaker Aleah; Adiguzel Cafer; Bakhos Mamdouh; Fareed Jawed
Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
Seminars in thrombosis and hemostasis 2008;34(1):74-85.
2008: Fareed Jawed; Hoppensteadt Debra A; Fareed Daniel; Demir Muzaffer; Wahi Rakesh; Clarke Melaine; Adiguzel Cafer; Bick Rodger
Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Seminars in thrombosis and hemostasis 2008;34(1):58-73.
2008: Hoppensteadt Debra A; Jeske Walter; Walenga Jeanine; Fareed Jawed
The future of anticoagulation.
Seminars in respiratory and critical care medicine 2008;29(1):90-9.
2008: Baker William F; Bick Rodger L; Fareed Jawed
Controversies and unresolved issues in antiphospholipid syndrome pathogenesis and management.
Hematology/oncology clinics of North America 2008;22(1):155-74, viii.
2008: Hoppensteadt Debra A; Fabbrini Nancy; Bick Rodger L; Messmore Harry L; Adiguzel Cafar; Fareed Jawed
Laboratory evaluation of the antiphospholipid syndrome.
Hematology/oncology clinics of North America 2008;22(1):19-32, v.
2008: Fareed Jawed; Bick Rodger L; Rao Gundu; Goldhaber Samuel Z; Sasahara Arthur; Messmore Harry L; Happensteadt Debra A; Nicolaides Andrew;
The immunogenic potential of generic version of low-molecular-weight heparins may not be the same as the branded products.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2008;14(1):5-7.
2008: Erez Offer; Romero Roberto; Hoppensteadt Debra; Fareed Jawed; Chaiworapongsa Tinnakorn; Kusanovic Juan Pedro; Mazaki-Tovi Shali; Gotsch Francesca; Than Nandor Gabor; Vaisbuch Edi; Kim Chong Jai; Espinoza Jimmy; Mittal Pooja; Hamill Neil; Nhan-Chang Chia-Ling; Mazor Moshe; Hassan Sonia
Premature labor: a state of platelet activation?
Journal of perinatal medicine 2008;36(5):377-87.
2007: Ravindranath Thyyar M; Goto Masakatsu; Iqbal Omer; Florian-Kujawski Michelle; Hoppensteadt Debra; Hammadeh Rashid; Sayeed Mohammad M; Fareed J
Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2007;13(4):362-8.
2007: Erez Offer; Hoppensteadt Debra; Romero Roberto; Espinoza Jimmy; Goncalves Luis; Nien Jyh Kae; Kusanovic Juan Pedro; Fareed Jawed; Gotsch Francesca; Pineles Beth; Chaiworapongsa Tinnakorn
Preeclampsia is associated with low concentrations of protein Z.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2007;20(9):661-7.
2007: Joyal Dominique; Leya Ferdinand; Obada Al-Chekakie M; Arab Dinesh; Dieter Robert S; Morshedi-Meibodi Ali; Lewis Bruce; Steen Lowell; Fareed Jawed; Hoppenstead Debra; Akar Joseph G
Presence of asymmetric dimethylarginine gradients across high-grade lesions in patients with coronary artery disease.
Coronary artery disease 2007;18(6):471-5.
2007: Anand Sunil X; Kim Michael C; Kamran Mazullah; Sharma Samin K; Kini Annapoorna S; Fareed Jawed; Hoppensteadt Debra A; Carbon Frank; Cavusoglu Erdal; Varon David; Viles-Gonzalez Juan F; Badimon Juan J; Marmur Jonathan D
Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin.
The American journal of cardiology 2007;100(3):417-24.
2007: Demir Muzaffer; Duran Enver; Yigitbasi Omer; Vural Ozden; Kurum Turhan; Yuksel Mahmut; Turgut Burhan; Walenga Jeanine M; Fareed Jawed
Incidence of antiheparin-platelet factor 4 antibodies and heparin-induced thrombocytopenia in Turkish patients undergoing cardiac surgery.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2007;13(3):279-84.
2007: Kusanovic Juan Pedro; Espinoza Jimmy; Romero Roberto; Hoppensteadt Debra; Nien Jyh Kae; Kim Chong Jai; Erez Offer; Soto Eleazar; Fareed Jawed; Edwin Sam; Chaiwerapongsa Tinnakorn; Than Nador G; Yoon Bo Hyun; Gomez Ricardo; Papp Zoltan; Hassan Sonia S
Plasma protein Z concentrations in pregnant women with idiopathic intrauterine bleeding and in women with spontaneous preterm labor.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2007;20(6):453-63.
2007: Fareed Jawed; Bick Rodger L; Kessler Craig; Messmore Harry L; Rao Gundu; Sasahara Arthur; Haas Sylvia
Potential thrombogenic complications with the use of recombinant activated factor VII in combat trauma.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2007;13(2):121-3.
2007: Maddineni Jyothi; Hoppensteadt Debra A; Cornelli Umberto; Manoni Marco; Fareed Jawed
Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2007;13(1):52-64.
2007: Fareed Jawed; Walenga Jeanine M
Why differentiate low molecular weight heparins for venous thromboembolism?
Thrombosis journal 2007;5():8.
2007: Ma Qing; Cornelli Umberto; Hanin Israel; Jeske Walter P; Linhardt Robert J; Walenga Jeanine M; Fareed Jawed; Lee John M
Heparin oligosaccharides as potential therapeutic agents in senile dementia.
Current pharmaceutical design 2007;13(15):1607-16.
2007: Rashid Rashid M; Lee John M; Fareed Jawed; Young M Rita I
In vitro heparan sulfate modulates the immune responses of normal and tumor-bearing mice.
Immunological investigations 2007;36(2):183-201.
2007: Ma Qing; Tobu Mahmut; Schultz Christopher; Jeske Walter; Hoppensteadt Debra; Walenga Jeanine; Cornelli Umberto; Lee John; Linhardt Robert; Hanin Israel; Fareed Jawed
Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides.
Thrombosis research 2007;119(5):653-61.
2006: Haas S; Breyer H G; Bacher H P; Fareed J; Misselwitz F; Victor N; Weber J;
Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
International angiology : a journal of the International Union of Angiology 2006;25(4):335-42.
2006: Deitcher Steven R; Kessler Craig M; Merli Geno; Rigas James R; Lyons Roger M; Fareed Jawed;
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2006;12(4):389-96.
2006: Fareed Jawed; Jeske Walter P; Hoppensteadt Debra A; Walenga Jeanine M
Update on the clinical applications of argatroban.
Future cardiology 2006;2(4):403-14.
2006: Maddineni Jyothi; Jeske Walter P; Baltasar Francis; Cornelli Umberto; Manoni Marco; Hoppensteadt Debra A; Fareed Jawed
Modulatory effects of Escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: flow cytometric analysis.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2006;12(3):311-7.
2006: Maddineni Jyothi; Walenga Jeanine M; Jeske Walter P; Hoppensteadt Debra A; Fareed Jawed; Wahi Rakesh; Bick Rodger L
Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2006;12(3):267-76.
2006: El Rouby Soumaya; Cohen Marc; Gonzales Andrea; Hoppensteadt Debra; Lee Ted; Zucker Marcia L; Khalid Khaula; Laduca Frank M; Fareed Jawed
The use of a HEMOCHRON JR. HEMONOX point of care test in monitoring the anticoagulant effects of enoxaparin during interventional coronary procedures.
Journal of thrombosis and thrombolysis 2006;21(2):137-45.
2006: Abdul-Jabar Hani Basil; Geroulakos George; Philpott Nicola; Fareed Jawed
Warfarin-induced skin necrosis: a case report.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2006;12(1):101-4.
2006: Guldiken Sibel; Turgut Burhan; Demir Muzaffer; Arikan Ender; Kara Mujdat; Vural Ozden; Tugrul Armagan; Fareed Jawed
The effects of rosiglitazone treatment on the fibrinolytic system in patients with type 2 diabetes mellitus.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2006;12(1):55-60.
2006: Messmore Harry L; Fareed Jawed; Bick Rodger L
Pitfalls in warfarin therapy.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2006;12(1):1-2.
2006: Haque Wasim; Fareed Jawed; Wehrmacher William H; Messmore Harry L
The classical vs nonclassical NSAIDs: can the reduction in pain overcome the thrombotic risk?
Comprehensive therapy 2006;32(4):261-6.
2006: Rashid Rashid M; Lee John M; Fareed Jawed; Young M Rita I
In vivo heparan sulfate treatment alters the immune response of normal and LLC-bearing mice.
Immunopharmacology and immunotoxicology 2006;28(1):67-79.
2006: Iqbal Omer; Fareed Jawed
Clinical applications of bioinformatics, genomics, and pharmacogenomics.
Methods in molecular biology (Clifton, N.J.) 2006;316():159-77.
2005: Haas Sylvia; Wolf Helmut; Kakkar Ajay K; Fareed Jawed; Encke Albrecht
Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin.
Thrombosis and haemostasis 2005;94(4):814-9.
2005: Messmore Harry L; Fareed Jawed; Walenga Jeanine M; Bick Rodger L
Argatroban and lepirudin: clinical trials to clinical practice.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2005;11(4):367-9.
2005: Fareed Jawed; Iqbal Omer; Nader Helena; Mousa Shaker; Wahi Rakesh; Coyne Erwin; Bick Rodger L
Generic low molecular weight heparins: a significant dilemma.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2005;11(4):363-6.
2005: Kannan Meganathan; Ahmad Sarfraz; Ahmad Firdos; Kale Shailaja; Hoppensteadt Debra A; Fareed Jawed; Saxena Renu
Functional characterization of antibodies against heparin-platelet factor 4 complex in heparin-induced thrombocytopenia patients in Asian-Indians: relevance to inflammatory markers.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2005;16(7):487-90.
2005: Walenga Jeanine M; Jeske Walter P; Fareed Jawed
Short- and long-acting synthetic pentasaccharides as antithrombotic agents.
Expert opinion on investigational drugs 2005;14(7):847-58.
2005: Fareed Jawed; Leong Wendy; Hoppensteadt Debra A; Jeske Walter P; Walenga Jeanine; Bick Rodger L
Development of generic low molecular weight heparins: a perspective.
Hematology/oncology clinics of North America 2005;19(1):53-68, v-vi.
2005: Bick Rodger L; Frenkel Eugene P; Walenga Jeanine; Fareed Jawed; Hoppensteadt Deborah A
Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use.
Hematology/oncology clinics of North America 2005;19(1):1-51, v.
2005: Kemkes-Matthes Bettina; Walenga Jeanine M; Harenberg Job; Fareed Jawed
Argatroban treatment for patients with intolerance to heparin and hirudin.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2005;11(1):99-103.
2005: Tobu M; Ma Q; Iqbal O; Schultz C; Jeske W; Hoppensteadt D A; Fareed J
Comparative tissue factor pathway inhibitor release potential of heparins.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2005;11(1):37-47.
2005: Iqbal O; Tobu M; Aziz S; Gerdisch M; Da Valle M; Demir M; Hoppensteadt D A; Ahmad S; Walenga J M; Fareed J
Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization.
Journal of cardiac surgery 2005;20(1):42-51.
2005: Fareed Jawed
New development in anticoagulant and antithrombotic therapy: are we on the right track?
Hematology (Amsterdam, Netherlands) 2005;10 Suppl 1():140-1.
2004: Florian-Kujawski M; Hoppensteadt D; Maddineni J; Ziegler H; Fareed J
Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implications.
International angiology : a journal of the International Union of Angiology 2004;23(4):346-54.
2004: Fareed Jawed; Leong Wendy L; Hoppensteadt Debra A; Jeske Walter P; Walenga Jeanine; Wahi Raisesh; Bick Rodger L
Generic low-molecular-weight heparins: some practical considerations.
Seminars in thrombosis and hemostasis 2004;30(6):703-13.
2004: Ma Qing; Fareed Jawed
Idraparinux sodium. Sanofi-Aventis.
IDrugs : the investigational drugs journal 2004;7(11):1028-34.
2004: Ravindranath Thyyar M; Goto Masakatsu; Demir Muzaffer; Tobu Mahmut; Kujawski M Florian; Hoppensteadt D; Samonte V; Iqbal Omer; Sayeed M M; Fareed J
Tissue factor pathway inhibitor and thrombin activatable fibrinolytic inhibitor plasma levels following burn and septic injuries in rats.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2004;10(4):379-85.
2004: Fareed D; Iqbal O; Tobu M; Hoppensteadt D A; Fareed J
Blood levels of nitric oxide, C-reactive protein, and tumor necrosis factor-alpha are upregulated in patients with malignancy-associated hypercoagulable state: pathophysiologic implications.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2004;10(4):357-64.
2004: Tobu Mahmut; Iqbal Omer; Hoppensteadt Debra; Neville Brian; Messmore Harry L; Fareed Jawed
Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2004;10(4):301-9.
2004: Fareed Jawed; Bick Rodger;
Differentiation of low-molecular-weight heparins: practical implications.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2004;10(4):299-300.
2004: Florian-Kujawski M; Hussain W; Chyna B; Kahn S; Hoppensteadt D; Leya F; Fareed J
Biomarker profiling of plasma from acute coronary syndrome patients. Application of ProteinChip Array analysis.
International angiology : a journal of the International Union of Angiology 2004;23(3):246-54.
2004: Zhang Fuming; Wu Yi; Ma Qing; Hoppensteadt Debra; Fareed Jawed; Linhardt Robert J
Studies on the effect of calcium in interactions between heparin and heparin cofactor II using surface plasmon resonance.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2004;10(3):249-57.
2004: Tobu Mahmut; Iqbal Omer; Fareed Daniel; Chatha Maninder; Hoppensteadt Debra; Bansal Vinod; Fareed Jawed
Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2004;10(3):225-32.
2004: Fareed Jawed; Jeske Walter P
Small-molecule direct antithrombins: argatroban.
Best practice & research. Clinical haematology 2004;17(1):127-38.
2004: Ahmad Sarfraz; Untch Brian; Haas Sylvia; Hoppensteadt Debra A; Misselwitz Frank; Messmore Harry L; Walenga Jeanine M; Fareed Jawed
Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis.
Molecular and cellular biochemistry 2004;258(1-2):163-70.
2004: Hoppensteadt Debra A; Fareed Jawed; Bick Rodger L
Epilogue. Expanded role of low-molecular-weight heparins in hematology and oncology.
Seminars in thrombosis and hemostasis 2004;30 Suppl 1():105-8.
2004: Fareed Jawed; Ma Qing; Florian Michelle; Maddineni Jyothi; Iqbal Omer; Hoppensteadt Debra A; Bick Rodger L
Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.
Seminars in thrombosis and hemostasis 2004;30 Suppl 1():89-104.
2004: Messmore Harry L; Wehrmacher William H; Coyne Erwin; Fareed Jawed
Heparin to pentasaccharide and beyond: the end is not in sight.
Seminars in thrombosis and hemostasis 2004;30 Suppl 1():81-8.
2004: Hoppensteadt Debra A; Willows Louise; Leitz Helen; Nicolaides Andrew; Fareed Jawed
Laboratory analysis of blood samples from patients treated with tinzaparin.
Seminars in thrombosis and hemostasis 2004;30 Suppl 1():49-55.
2004: Jeske Walter; Fareed Jawed
Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates.
Seminars in thrombosis and hemostasis 2004;30 Suppl 1():41-7.
2004: Gül Cetin; Kürüm Turhan; Demir Muzaffer; Ozbay Gültaç; Vural Ozden; Iqbal Omer; Fareed Jawed
Acute myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2004;10(1):77-9.
2004: Kannan Meganathan; Ahmed Rafeeq; Kale Shailaja; Ahmad Sarfraz; Fareed Jawed; Saxena Renu
Laboratory diagnosis of heparin-induced thrombocytopenia in Asian Indians as investigated with functional and immunologic methods.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2004;10(1):51-4.
2004: Maddineni Jyothi; Ma Qing; Hoppensteadt Debra A; Demir Muzaffer; Manoni Marco; Cornelli Umberto; Fareed Jawed
Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2004;10(1):27-37.
2004: Messmore H L; Coyne E; Wehrmacher W H; Demir A M; Fareed J
Studies comparing low molecular weight heparin with heparin for the treatment of thromboembolism: a literature review.
Current pharmaceutical design 2004;10(9):1001-10.
2004: Fareed Jawed; Hoppensteadt Debra; Schultz Christopher; Ma Qing; Kujawski Michelle Florian; Neville Brian; Messmore Harry
Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile.
Current pharmaceutical design 2004;10(9):983-99.
2004: Jeske Walter P; Iqbal Omer; Fareed Jawed; Kaiser Brigitte
A survey of venous thrombosis models.
Methods in molecular medicine 2004;93():221-37.
2004: Mousa Shaker A; Fareed Jawed; Iqbal Omer; Kaiser Brigitte
Tissue factor pathway inhibitor in thrombosis and beyond.
Methods in molecular medicine 2004;93():133-55.
2004: Walenga Jeanine M; Jeske Walter P; Hoppensteadt Debra; Fareed Jawed
Factor Xa inhibitors.
Methods in molecular medicine 2004;93():95-117.
2003: Gerbutavicius Rolandas; Iqbal Omer; Messmore Harry L; Wehrmacher William H; Hoppensteadt Debra A; Gerbutaviciene Rima; Griniute Rasa; Fareed Jawed
Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2003;9(4):317-23.
2003: Tobu M; Iqbal O; Messmore H L; Ma Q; Hoppensteadt D A; Fareed J
Influence of different anticoagulant agents on fibrinopeptide a generation.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2003;9(4):273-92.
2003: Stief Thomas W; Fareed Jawed
Point of care: diagnostics in hemostasis--the wrong direction?
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2003;9(3):191-5.
2003: Ahmad Sarfraz; Bacher H Peter; Lassen Michael R; Hoppensteadt Debra A; Leitz Helen; Misselwitz Frank; Walenga Jeanine M; Fareed Jawed
Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients.
Archives of pathology & laboratory medicine 2003;127(5):584-8.
2003: Fareed Jawed; Hoppensteadt Debra A; Bick Rodger L
Management of thrombotic and cardiovascular disorders in the new millenium.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2003;9(2):101-8.
2003: Iqbal Omer; Eklof Bo; Tobu Mahmut; Fareed Jawed
Air travel-associated venous thromboembolism.
Medical principles and practice : international journal of the Kuwait University, Health Science Centre 2003;12(2):73-80.
2003: Walenga Jeanine M; Jeske Walter P; Hoppensteadt Debra; Fareed Jawed
Factor Xa inhibitors: today and beyond.
Current opinion in investigational drugs (London, England : 2000) 2003;4(3):272-81.
2003: Hoppensteadt Debra; Walenga Jeanine M; Fareed Jawed; Bick Rodger L
Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.
Hematology/oncology clinics of North America 2003;17(1):313-41.
2003: Marmur Jonathan D; Anand Sunil X; Bagga Ramanjit S; Fareed Jawed; Pan Chi-Miau; Sharma Samin K; Richard Merwin F
The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration.
Journal of the American College of Cardiology 2003;41(3):394-402.
2003: Tobu Mahmut; Iqbal Omer; Ma Qing; Schultz Christopher; Jeske Walter; Hoppensteadt Debra; Lewis Bruce; Fareed Daniel; Fareed Jawed
Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2003;9(1):1-17.
2003: Ma Qing; Schultz Christopher; Neville Brian; Jeske Walter; Hoppensteadt Debra; Cornelli Umberto; Lee John; Lorens Stanley; Hanin Israel; Fareed Jawed
Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primates.
Thrombosis research 2003;112(4):249-55.
2003: Fareed Jawed; Hoppensteadt Debra; Walenga Jeanine; Iqbal Omer; Ma Qing; Jeske Walter; Sheikh Taqdees
Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.
Clinical pharmacokinetics 2003;42(12):1043-57.
2002: Ahmad Sarfraz; Haas Sylvia; Hoppensteadt Debra A; Lietz Helen; Reid Ulrike; Bender Norbert; Messmore Harry L; Misselwitz Frank; Bacher Peter; Gaikwad Bhavna S; Jeske Walter P; Walenga Jeanine M; Fareed Jawed
Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies.
Thrombosis research 2002;108(1):49-55.
2002: Tobu Mahmut; Iqbal Omer; Hoppensteadt Debra A; Shultz Christopher; Jeske Walter; Fareed Jawed
Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2002;8(4):325-36.
2002: Yu Guangli; Gunay Nur Sibel; Linhardt Robert J; Toida Toshihiko; Fareed Jawed; Hoppensteadt Debra A; Shadid Hazar; Ferro Vito; Li Caiping; Fewings Kym; Palermo Maria C; Podger Denis
Preparation and anticoagulant activity of the phosphosulfomannan PI-88.
European journal of medicinal chemistry 2002;37(10):783-91.
2002: George Magdalene M; Van Thiel David H; Tarasuk George; Chejfec Gregorio; McClatchey Kenneth D; Hamdani Raza; Fareed Jawed
Hemostatic modulation with the liver dialysis device in humans with advanced liver disease.
Hepato-gastroenterology 2002;49(47):1333-9.
2002: Iqbal Omer; Ahmad Sarfraz; Lewis Bruce E; Walenga Jeanine M; Rangel Yadira; Fareed Jawed
Monitoring of argatroban in ARG310 study: potential recommendations for its use in interventional cardiology.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2002;8(3):217-24.
2002: Mousa Shaker A; Iqbal Omar; Fareed Jawed
Antithrombotics and thrombolytics in stroke.
Current opinion in investigational drugs (London, England : 2000) 2002;3(6):878-85.
2002: Walzer Mark; Lorens Stanley; Hejna Matthew; Fareed Jawed; Hanin Israel; Cornelli Umberto; Lee John M
Low molecular weight glycosaminoglycan blockade of beta-amyloid induced neuropathology.
European journal of pharmacology 2002;445(3):211-20.
2002: Iqbal Omer; Messmore Harry; Fareed Jawed; Ahmad Sarfraz; Hoppensteadt Debra; Hazar Shadid; Tobu Mahmut; Aziz Salim; Wehrmacher William
Antithrombotic agents in the treatment of severe sepsis.
Expert opinion on emerging drugs 2002;7(1):111-39.
2002: Untch Brian; Ahmad Sarfraz; Messmore Harry L; Schultz Christopher L; Ma Qing; Hoppensteadt Debra A; Walenga Jeanine M; Fareed Jawed
Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies.
Thrombosis research 2002;106(2):149-56.
2002: Gerbutavicius Rolandas; Fareed Jawed; Messmore Harry L; Iqbal Omer; Hoppensteadt Debra A; Wehrmacher William H; Demir Muzaffer; Piccolo Peter; Ahmad Sarfraz; Ma Qing; Griniute Rasa
Reference intervals of the dilute tissue thromboplastin inhibition and dilute Russell's viper venom tests revisited.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2002;8(2):115-24.
2002: Ma Qing; Dudas Bertalan; Hejna Matthew; Cornelli Umberto; Lee John M; Lorens Stanley; Mervis Ronald; Hanin Israel; Fareed Jawed
The blood-brain barrier accessibility of a heparin-derived oligosaccharides C3.
Thrombosis research 2002;105(5):447-53.
2002: Kakkar Vijay V; Hoppenstead Debra A; Fareed Jawed; Kadziola Zbigniew; Scully Mike; Nakov Roumen; Breddin Hans K
Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis.
Blood 2002;99(6):1965-70.
2002: Walenga Jeanine M; Jeske Walter P; Samama M Michel; Frapaise F Xavier; Bick Rodger L; Fareed Jawed
Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent.
Expert opinion on investigational drugs 2002;11(3):397-407.
2002: Ma Qing; Dudas Bertalan; Daud Asif; Iqbal Omer; Hoppensteadt Debra; Jeske Walter; Cornelli Umberto; Lee John; Lorens Stanley; Mervis Ronald; Hanin Israel; Capila Ishan; Linhardt Robert; Fareed Jawed
Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3.
Thrombosis research 2002;105(4):303-9.
2002: Gerbutavicius Rolandas; Fareed Jawed; Messmore Harry L; Iqbal Omer; Wehrmacher William H; Hoppensteadt Debra A; Demir Muzaffer; Piccolo Peter; Ahmad Sarfraz; Ma Qing; Griniute Rasa
Reference ranges of the dilute tissue thromboplastin inhibition and dilute Russell's viper venom tests revisited.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2002;8(1):51-9.
2002: Untch Brian; Ahmad Sarfraz; Jeske Walter P; Messmore Harry L; Hoppensteadt Debra A; Walenga Jeanine M; Lietz Helen; Fareed Jawed
Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG.
Thrombosis research 2002;105(2):117-23.
2002: Fareed Jawed; Hoppensteadt Debra; Iqbal Omer; Tobu Mehmut; Lewis Bruce E
Practical issues in the development of argatroban: a perspective.
Pathophysiology of haemostasis and thrombosis 2002;32 Suppl 3():56-65.
2001: Grassman E D; Leya F; Fareed J; Lewis B E; Bacher P; Loeb H S; Moran J F
A randomized trial of the low-molecular-weight heparin certoparin to prevent restenosis following coronary angioplasty.
The Journal of invasive cardiology 2001;13(11):723-8.
2001: Fareed J; Shaikh T; Hoppensteadt D A
Antithrombin and anti-Xa agents in the control of thrombogenesis.
Die Pharmazie 2001;56 Suppl 1():S12-21.
2001: Hoppensteadt D A; Fareed J; Raake P; Raake W
Endogenous release of tissue factor pathway inhibitor by topical application of an ointment containing mucopolysaccharide polysulfate to nonhuman primates.
Thrombosis research 2001;103(2):157-63.
2001: Iqbal O; Aziz S; Hoppensteadt D A; Ahmad S; Walenga J M; Bakhos M; Fareed J
Emerging anticoagulant and thrombolytic drugs.
Expert opinion on emerging drugs 2001;6(1):111-35.
2001: Van Thiel D H; George M; Fareed J
Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease.
Thrombosis and haemostasis 2001;85(4):667-70.
2001: Ahmad S; Jeske W P; Ma Q; Walenga J M; Fareed J
Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist.
Thrombosis research 2001;102(2):143-51.
2001: Lewis B E; Wallis D E; Berkowitz S D; Matthai W H; Fareed J; Walenga J M; Bartholomew J; Sham R; Lerner R G; Zeigler Z R; Rustagi P K; Jang I K; Rifkin S D; Moran J; Hursting M J; Kelton J G;
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.
Circulation 2001;103(14):1838-43.
2001: Piccolo P; Iqbal O; Demir M; Ma Q; Gerbutavicius R; Fareed J
Global anticoagulant effects of a novel sulfated pentomanan oligosaccharide mixture.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2001;7(2):149-52.
2001: Demir M; Iqbal O; Hoppensteadt D A; Piccolo P; Ahmad S; Schultz C L; Linhardt R J; Fareed J
Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88).
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2001;7(2):131-40.
2001: Daud A N; Ahsan A; Iqbal O; Walenga J M; Silver P J; Ahmad S; Fareed J
Synthetic heparin pentasaccharide depolymerization by heparinase I: molecular and biological implications.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2001;7(1):58-64.
2001: Demir M; Iqbal O; Dietrich C P; Hoppensteadt D A; Ahmad S; Daud A N; Fareed J
Anticoagulant and antiprotease effects of a novel heparinlike compound from shrimp (Penaeus brasiliensis) and its neutralization by heparinase I.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2001;7(1):44-52.
2001: Demir M; Iqbal O; Untch B; Hoppensteadt D A; Gaikwad B S; Fareed J
Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2001;7(1):38-43.
2001: Orcullo Santillan M K; Herring J; Hoppensteadt D A; Jeske W; Herbert J M; Fareed J
The effect of a novel glycoprotein IIb/IIIa antagonist, SR 121566A, on platelet aggregation and activation in rhesus monkeys.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2001;7(1):10-5.
2000: Yu G; LeBrun L; Gunay N S; Hoppensteadt D; Walenga J M; Fareed J; Linhardt R J
Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site.
Thrombosis research 2000;100(6):549-56.
2000: Ahmad S; Jeske W P; Walenga J M; Aldabbagh A; Iqbal O; Fareed J
Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: towards the development of a HIT model in primates.
Thrombosis research 2000;100(1):47-54.
2000: Gerbutavicius R; Iqbal O; Messmore H; Hoppensteadt D A; Demir M; Khan E; Bacher P; Fareed J
Differential effects of unfractionated heparin and low-molecular-weight heparins on tissue thromboplastin inhibition test.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2000;6(4):190-6.
2000: Ahsan A; Jeske W; Wolf H; Fareed J
Isoamyl nitrite depolymerized heparin as a universal calibrator for heparins and low molecular weight heparins.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2000;6(3):169-74.
2000: Ahmad S; Yang L H; Ahsan A; Fu K; Iqbal O; Hoppensteadt D A; Lewis B E; Walenga J M; Fareed J
Pharmacokinetics of argatroban in primates: evidence on endogenous uptake.
International angiology : a journal of the International Union of Angiology 2000;19(2):126-34.
2000: Amin H M; Ahmad S; Walenga J M; Hoppensteadt D A; Leitz H; Fareed J
Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disorders.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2000;6(2):71-6.
2000: Kaiser B; Paintz M; Scholz O; Kunitada S; Fareed J
A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats.
Thrombosis research 2000;98(2):175-85.
2000: Iqbal O; Messmore H; Hoppensteadt D; Fareed J; Wehrmacher W
Thrombolytic drugs in acute myocardial infarction.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2000;6(1):1-13.
2000: Fareed J; Hoppensteadt D A; Bick R L
An update on heparins at the beginning of the new millennium.
Seminars in thrombosis and hemostasis 2000;26 Suppl 1():5-21.
1999: Kaiser B; Jeske W; Walenga J M; Fareed J
Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1999;10(8):495-501.
1999: Fareed J; Lewis B E; Callas D D; Hoppensteadt D A; Walenga J M; Bick R L
Antithrombin agents: the new class of anticoagulant and antithrombotic drugs.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 1999;5 Suppl 1():S45-55.
1999: Fareed J; Walenga J M; Hoppensteadt D A; Jeske W P; Ahmad S; Lietz H; McKenna R; Messmore H L; Haas S
Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulation.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 1999;5 Suppl 1():S38-44.
1999: Ahmad S; Walenga J M; Jeske W P; Cella G; Fareed J
Functional heterogeneity of antiheparin-platelet factor 4 antibodies: implications in the pathogenesis of the HIT syndrome.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 1999;5 Suppl 1():S32-7.
1999: Ahmad S; Jeske W P; Walenga J M; Hoppensteadt D A; Wood J J; Herbert J M; Messmore H L; Fareed J
Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 1999;5(4):259-66.
1999: Ahmad S; Ahsan A; George M; Iqbal O; Jeske W P; McKenna R; Lewis B E; Walenga J M; Fareed J
Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applications.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 1999;5(4):252-8.
1999: Hoppensteadt D A; Jeske W P; Walenga J M; Fu K; Yang L H; Ing T S; Herbert J M; Fareed J
Laboratory monitoring of pentasaccharide in a dog model of hemodialysis.
Thrombosis research 1999;96(2):115-24.
1999: Ahmad S; Iqbal O; Ahsan A; Hoppensteadt D A; Lewis B E; Walenga J M; Fareed J
Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using high performance liquid chromatography and functional methods.
International angiology : a journal of the International Union of Angiology 1999;18(3):198-205.
1999: Jeske W; Walenga J M; Lewis B E; Fareed J
Pharmacology of argatroban.
Expert opinion on investigational drugs 1999;8(5):625-54.
1999: Fareed J; Hoppensteadt D A; Leya F; Lewis B; Callas D; Wolf H; Bick R L
Thrombogenesis in myocardial infarction and related syndromes: the role of molecular markers in diagnosis and management.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 1999;5(2):78-91.
1999: Jeske W; Wolf H; Ahsan A; Fareed J
Pharmacologic profile of certoparin.
Expert opinion on investigational drugs 1999;8(3):315-27.
1999: Fareed J; Callas D; Hoppensteadt D A; Lewis B E; Bick R L; Walenga J M
Antithrombin agents as anticoagulants and antithrombotics: implications in drug development.
Seminars in hematology 1999;36(1 Suppl 1):42-56.
1999: Fareed J; Fu K; Yang L H; Hoppensteadt D A
Pharmacokinetics of low molecular weight heparins in animal models.
Seminars in thrombosis and hemostasis 1999;25 Suppl 3():51-5.
1999: Kaiser B; Kirchmaier C M; Breddin H K; Fu K; Fareed J
Preclinical biochemistry and pharmacology of low molecular weight heparins in vivo--studies of venous and arterial thrombosis.
Seminars in thrombosis and hemostasis 1999;25 Suppl 3():35-42.
1999: Jeske W; Fareed J
In vitro studies on the biochemistry and pharmacology of low molecular weight heparins.
Seminars in thrombosis and hemostasis 1999;25 Suppl 3():27-33.
1999: Fareed J; Hoppensteadt D A; Jeske W P; Ahmad S; Bick R L
Acquired defects of fibrinolysis associated with thrombosis.
Seminars in thrombosis and hemostasis 1999;25(4):367-74.
1999: Walenga J M; Jeske W P; Wallis D E; Bakhos M; Lewis B E; Leya F; Fareed J
Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT.
Seminars in thrombosis and hemostasis 1999;25 Suppl 1():77-81.
1999: Izban K F; Lietz H W; Hoppensteadt D A; Jeske W P; Fareed J; Bakhos M; Walenga J M
Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia.
Seminars in thrombosis and hemostasis 1999;25 Suppl 1():51-6.
1999: Fareed J; Walenga J M; Hoppensteadt D A; Jeske W P; Lietz H; Ahmad S; Callas D; Messmore H L; Haas S
Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation.
Seminars in thrombosis and hemostasis 1999;25 Suppl 1():37-42.
1998: Blair S J; Chinthagada M; Hoppenstehdt D; Kijowski R; Fareed J
Role of neuropeptides in pathogenesis of reflex sympathetic dystrophy.
Acta orthopaedica Belgica 1998;64(4):448-51.
1998: Yang L H; Hoppensteadt D; Fareed J
Modulation of vasoconstriction by clopidogrel and ticlopidine.
Thrombosis research 1998;92(2):83-9.
1998: Kaiser B; Glusa E; Hoppensteadt D A; Breddin H K; Amiral J; Fareed J
A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1998;9(6):517-23.
1998: Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga J M
Low-molecular-weight heparins: pharmacologic profile and product differentiation.
The American journal of cardiology 1998;82(5B):3L-10L.
1998: Fareed J; Hoppensteadt D; Jeske W; Clarizio R; Walenga J M
Low molecular weight heparins: are they different?
The Canadian journal of cardiology 1998;14 Suppl E():28E-34E.
1998: Fareed J; Hoppensteadt D A; Leya F; Iqbal O; Wolf H; Bick R
Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes.
Clinical chemistry 1998;44(8 Pt 2):1845-53.
1998: Kaiser B; Callas D; Walenga J M; Fareed J
Synthetic and recombinant antithrombin drugs.
Expert opinion on investigational drugs 1998;7(6):963-85.
1998: Coyne E; Messmore H L; Walenga J M; Fareed J; Wehrmacher W H
Ethylenediaminetetraacetic acid (EDTA) in heparin.
Thrombosis research 1998;90(5):245-6.
1998: Fareed J; Callas D; Hoppensteadt D A; Walenga J M; Bick R L
Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development.
The Medical clinics of North America 1998;82(3):569-86.
1998: Lewis B E; Rangel Y; Fareed J
The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome: a case report.
Angiology 1998;49(1):61-7.
1997: Hoppensteadt D A; Jeske W P; Walenga J M; Fu K; Yang L H; Ing T; Herbert J M; Fareed J
Efficacy of pentasaccharide in a dog model of hemodialysis.
Thrombosis research 1997;88(2):159-70.
1997: Kaiser B; Jeske W; Hoppensteadt D H; Walenga J M; Drohan W; Fareed J
In vitro studies on the effect of activated protein C on platelet activation and thrombin generation.
Thrombosis research 1997;87(2):197-204.
1997: Fareed J; Hoppensteadt D; Jeske W; Clarizio R; Walenga J M
Low molecular weight heparins: a developmental perspective.
Expert opinion on investigational drugs 1997;6(6):705-33.
1997: Yang L H; Fareed J
Vasomodulatory action of clopidogrel and ticlopidine.
Thrombosis research 1997;86(6):479-91.
1997: Fu K; Izquierdo R; Vandevender D; Warpeha R L; Wolf H; Fareed J
Topical application of low molecular weight heparin in a rabbit traumatic anastomosis model.
Thrombosis research 1997;86(5):355-61.
1997: Walenga J M; Jeske W P; Bara L; Samama M M; Fareed J
Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.
Thrombosis research 1997;86(1):1-36.
1997: Jeske W; Fareed J; Eschenfelder V; Iqbal O; Hoppensteadt D; Ahsan A
Biochemical and pharmacologic characteristics of Reviparin, a low-molecular-mass heparin.
Seminars in thrombosis and hemostasis 1997;23(2):119-28.
1996: Yang L H; Hoppensteadt D A; Iqbal O; Fareed J
Defibrotide mediated inhibition of serotonin, endothelin-I, thromboxane, and serum induced contraction of canine femoral and pulmonary arterial rings.
Thrombosis research 1996;84(3):167-77.
1996: Callas D D; Fareed J
Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method.
Thrombosis research 1996;83(6):463-8.
1996: Callas D D; Fareed J
Comparative studies on the antithrombin potency of various thrombin inhibitors, as determined by using an amidolytic method.
Thrombosis research 1996;83(1):97-102.
1996: Hayes J M; Jeske W; Callas D; Iqbal O; Fareed J
Comparative intravenous antithrombotic actions of heparin and site directed thrombin inhibitors in a jugular vein clamping model.
Thrombosis research 1996;82(2):187-91.
1996: Yang L H; Callas D; Herbert J M; Fareed J
Modulation of platelet function and vascular smooth muscle contractile actions by a novel, selective, highly potent 5-HT2 antagonist (SR46349).
Thrombosis research 1996;81(5):555-67.
1996: Hoppensteadt D A; Jeske W; Fareed J; Nicolaides A N
Physical and pharmacologic manipulation of the vascular system as measured by the release of TFPI and other mediators of antithrombotic actions.
International angiology : a journal of the International Union of Angiology 1996;15(1):39-46.
1996: Fareed J; Hoppensteadt D A
Pharmacology of the low-molecular-weight heparins.
Seminars in thrombosis and hemostasis 1996;22 Suppl 2():13-8.
1996: Fareed J; Jeske W; Eschenfelder V; Iqbal O; Hoppensteadt D; Ahsan A
Preclinical studies on a low molecular weight heparin.
Thrombosis research 1996;81(2 Suppl):S1-27.
1996: Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga J M
Are the available low-molecular-weight heparin preparations the same?
Seminars in thrombosis and hemostasis 1996;22 Suppl 1():77-91.
1996: Fareed J
Current trends in antithrombotic drug and device development.
Seminars in thrombosis and hemostasis 1996;22 Suppl 1():3-8.
1996: Jeske W; Hoppensteadt D; Callas D; Koza M J; Fareed J
Pharmacological profiling of recombinant tissue factor pathway inhibitor.
Seminars in thrombosis and hemostasis 1996;22(2):213-9.
1995: Hoppensteadt D A; Fasanella A; Fareed J
Effect of protamine on heparin releasable TFPI antigen levels in normal volunteers.
Thrombosis research 1995;79(3):325-30.
1995: Callas D; Fareed J
Comparative pharmacology of site directed antithrombin agents. Implication in drug development.
Thrombosis and haemostasis 1995;74(1):473-81.
1995: Chamberlin J R; Lewis B; Leya F; Wallis D; Messmore H; Hoppensteadt D; Walenga J M; Moran S; Fareed J; McKiernan T
Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog.
The Canadian journal of cardiology 1995;11(6):511-4.
1995: Fu K; Izquierdo R; Walenga J M; Fareed J
Comparative study on the use of anticoagulants heparin and recombinant hirudin in a rabbit traumatic anastomosis model.
Thrombosis research 1995;78(5):421-8.
1995: Jeske W; Hoppensteadt D; Fareed J; Bermes E
Measurement of functional and immunologic levels of tissue factor pathway inhibitor. Some methodologic considerations.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1995;6 Suppl 1():S73-80.
1995: Hoppensteadt D A; Jeske W; Fareed J; Bermes E W
The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1995;6 Suppl 1():S57-64.
1995: Fareed J; Callas D D; Hoppensteadt D; Bermes E W
Tissue factor antigen levels in various biological fluids.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1995;6 Suppl 1():S32-6.
1995: Ahsan A; Jeske W; Hoppensteadt D; Lormeau J C; Wolf H; Fareed J
Molecular profiling and weight determination of heparins and depolymerized heparins.
Journal of pharmaceutical sciences 1995;84(6):724-7.
1995: Callas D D; Fareed J
Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy.
Thrombosis research 1995;78(5):457-60.
1995: Iyer L; Fareed J
Determination of specific activity of recombinant hirudin using a thrombin titration method.
Thrombosis research 1995;78(3):259-63.
1995: Jeske W; Hoppensteadt D; Klauser R; Kammereit A; Eckenberger P; Haas S; Wyld P; Fareed J
Effect of repeated Aprosulate and Enoxaparin administration on tissue factor pathway inhibitor antigen levels.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1995;6(2):119-24.
1995: Fareed J; Bick R L; Hoppensteadt D A; Walenga J M; Messmore H L; Bermes E W
Molecular markers of hemostatic activation. Implications in the diagnosis of thrombosis, vascular, and cardiovascular disorders.
Clinics in laboratory medicine 1995;15(1):39-61.
1995: Koza M J; Shankey T C; Walenga J M; Moncada R; Fareed J; Pifarre R
Flow cytometric evaluation of platelet activation by ionic or nonionic contrast media and modulation by heparin and recombinant hirudin.
Investigative radiology 1995;30(2):90-7.
1995: Hoppensteadt D A; Walenga J M; Fasanella A; Jeske W; Fareed J
TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin.
Thrombosis research 1995;77(2):175-85.
1995: Iqbal O; Jeske W; Hoppensteadt D; Koza M; Walenga J M; Fareed J; Moncada R
Procoagulant and anticoagulant effects of intravascular contrast media as assessed by thromboelastography.
Seminars in thrombosis and hemostasis 1995;21 Suppl 4():86-90.
1995: Iqbal O; Jeske W; Hoppensteadt D; Walenga J M; Fareed J
The approach of thromboelastography in the monitoring of new synthetic antithrombotic agents, GL-522 and GL-2021.
Seminars in thrombosis and hemostasis 1995;21 Suppl 4():72-5.
1995: Lojewski B; Bacher P; Iqbal O; Walenga J M; Hoppensteadt D; Leya F; Fareed J
Evaluation of hemostatic and fibrinolytic alterations associated with daily administration of low-molecular-weight heparin for a 12-week period.
Seminars in thrombosis and hemostasis 1995;21(2):228-39.
1995: Fareed J; Jeske W; Eschenfelder V; Iqbal O; Hoppensteadt D; Ahsan A
Pharmacologic validation of the clinical effects of an optimized low-molecular-weight heparin-reviparin.
Seminars in thrombosis and hemostasis 1995;21(2):212-27.
1995: Jeske W; Lormeau J C; Callas D; Iqbal O; Hoppensteadt D; Fareed J
Antithrombin III affinity dependence on the anticoagulant, antiprotease, and tissue factor pathway inhibitor actions of heparins.
Seminars in thrombosis and hemostasis 1995;21(2):193-200.
1995: Iyer L; Adam M; Amiral J; Fareed J; Bermes E
Development and validation of two enzyme-linked immunosorbent assay (ELISA) methods for recombinant hirudin.
Seminars in thrombosis and hemostasis 1995;21(2):184-92.
1995: Callas D D; Hoppensteadt D; Fareed J
Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin.
Seminars in thrombosis and hemostasis 1995;21(2):177-83.
1995: Callas D D; Bacher P; Fareed J
Studies on the thrombogenic effects of recombinant tissue factor. In vivo versus ex vivo findings.
Seminars in thrombosis and hemostasis 1995;21(2):166-76.
1995: Fareed J; Hoppensteadt D; Iyer L; Koza M; Walenga J M; Bermes E
Impact of biotechnology in the diagnostic and therapeutic management of cardiovascular disorders.
Advances in experimental medicine and biology 1995;369():99-110.
1994: Kaiser B; Jeske W; Hoppensteadt D; Fareed J
Inhibitory effects of TFPI variants on thrombin and factor Xa generation in fibrinogen-deficient human plasma.
Thrombosis research 1994;76(6):561-8.
1994: Walenga J M; Fareed J
Automation and quality control in the coagulation laboratory.
Clinics in laboratory medicine 1994;14(4):709-28.
1994: Kaiser B; Hoppensteadt D A; Jeske W; Wun T C; Fareed J
Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans.
Thrombosis research 1994;75(6):609-16.
1994: Fareed J; Hoppensteadt D; Walenga J M; Bick R L
Current trends in the development of anticoagulant and antithrombotic drugs.
The Medical clinics of North America 1994;78(3):713-31.
1994: Callas D; Bacher P; Iqbal O; Hoppensteadt D; Fareed J
Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin.
Thrombosis research 1994;74(3):193-205.
1994: Kijowski R; Hoppensteadt D; Walenga J; Borris L; Lassen M R; Fareed J
Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin.
Thrombosis research 1994;74(1):53-64.
1994: Kijowski R; Hoppensteadt D; Jeske W; Fareed J
Protamine sulfate neutralization of the anticoagulant activity of Aprosulate, a synthetic sulfated lactobionic acid amide.
Thrombosis research 1994;73(5):349-59.
1994: Kaiser B; Callas D; Hoppensteadt D; Mallinowska K; Fareed J
Comparative studies on the inhibitory spectrum of recombinant hirudin, DuP 714 and heparin on thrombin and factor Xa generation in biochemically defined systems.
Thrombosis research 1994;73(5):327-35.
1994: Ahsan A; Jeske W; Mardiguian J; Fareed J
Feasibility study of heparin mass calibrator as a GPC calibrator for heparins and low molecular weight heparins.
Journal of pharmaceutical sciences 1994;83(2):197-201.
1993: Hoppensteadt D; Jeske W; Fareed J
Pharmacological profile of reviparin-sodium.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1993;4 Suppl 1():S11-6.
1993: Bacher P; Walenga J M; Iqbal O; Bajusz S; Breddin K; Fareed J
The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models.
Thrombosis research 1993;71(4):251-63.
1993: Bacher P; Iqbal O; Lojewski B; Walenga J M; Leya F; Fareed J
A simulated post-angioplasty low molecular weight heparin schedule in a non-human primate model.
Thrombosis research 1993;70(4):295-306.
1993: Bacher P; Kindel G; Walenga J M; Fareed J
Modulation of endothelial and platelet function by a polydeoxyribonucleotide derived drug "defibrotide". A dual mechanism in the control of vascular pathology.
Thrombosis research 1993;70(4):343-8.
1993: Jeske W; Ahsan A; Fareed J
Molecular weight profiling of low molecular weight heparins utilizing a heparinase degraded oligosaccharide mixture as a calibrator.
Thrombosis research 1993;70(1):39-50.
1993: Najman D M; Walenga J M; Fareed J; Pifarré R
Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery.
The Annals of thoracic surgery 1993;55(3):662-6.
1993: Iyer L; Koza M; Iqbal O; Calabria R; Fareed J
Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogs.
Thrombosis research 1993;69(3):259-69.
1993: Callas D D; Ahsan A; Iqbal O; Fareed J
Molecular weight and biochemical profile of a chemically modified heparin derivative, Suleparoide.
Thrombosis research 1993;69(4):369-76.
1993: Iyer L; Shavit J; Koza M; Calabria R; Moran S; Fareed J
Alteration of pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after repeated intravenous administration in dogs.
Thrombosis research 1993;69(1):59-70.
1993: Bacher P; Horst B; Breyer H G; Hoppensteadt D A; Walenga J M; Fareed J
Postoperative monitoring of low molecular weight heparin prophylaxis in high-risk patients.
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():73-8.
1993: Ahsan A; Jeske W; Fareed J
Validation of the European Pharmacopeial method for molecular weight profiling of low molecular weight heparins: comparative studies utilizing an improved calibrator, ITH-3.
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():63-8.
1993: Malinowska K; Iqbal O; Hoppensteadt D A; Walenga J M; Fareed J
In vivo study of bleeding and antithrombotic effects of low molecular weight heparin ML-009723.
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():58-62.
1993: Lojewski B; Bacher P; Iqbal O; Walenga J M; Hoppensteadt D A; Leya F; Fareed J
Evaluation of hematologic alterations associated with daily administration of low molecular weight heparin (Mono-Embolex) for a 12-week period.
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():36-43.
1993: Hoppensteadt D A; Haas S; Breddin H K; Fareed J
Modulation of laboratory parameters after therapeutic and prophylactic administration of Sandoparin.
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():31-5.
1993: Jeske W; Lojewski B; Walenga J M; Hoppensteadt D; Ahsan A; Fareed J
Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin).
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():229-40.
1993: Iqbal O; Jeske W; Bacher P; Hoppensteadt D A; Walenga J M; Fareed J
A comparison of the pharmacokinetic and pharmacodynamic profiles of Clexane and Lovenox in dogs.
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():199-209.
1993: Fareed J; Hoppensteadt D A; Walenga J M
Current perspectives on low molecular weight heparins.
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():1-11.
1993: Koza M J; Walenga J M; Fareed J; Pifarre R
A new approach in monitoring recombinant hirudin during cardiopulmonary bypass.
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():90-6.
1993: Callas D D; Hoppensteadt D A; Jeske W; Iqbal O; Bacher P; Ahsan A; Fareed J
Comparative pharmacologic profile of a glycosaminoglycan mixture, Sulodexide, and a chemically modified heparin derivative, Suleparoide.
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():49-57.
1993: Jeske W; Fareed J
Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues.
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():241-7.
1993: Hoppensteadt D A; Jeske W; Ahsan A; Walenga J M; Fareed J
Biochemical and pharmacologic profile of defined molecular weight fractions of heparin.
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():12-9.
1992: Fareed J; Hoppenstedt D; Bick R L; Bacher P
Drug-induced alterations of hemostasis and fibrinolysis.
Hematology/oncology clinics of North America 1992;6(6):1229-45.
1992: Racanelli A; Fareed J
Neutralization of the antithrombotic effects of heparin and Fraxiparin by protamine sulfate.
Thrombosis research 1992;68(3):211-22.
1992: Hoppensteadt D; Walenga J M; Fareed J
Low molecular weight heparins. An objective overview.
Drugs & aging 1992;2(5):406-22.
1992: Racanelli A; Fareed J
Ex vivo activity of heparin is not predictive of blood loss after neutralization by protamine.
Thrombosis research 1992;67(2):263-73.
1992: Fareed J; Bacher P; Messmore H L; Walenga J M; Hoppensteadt D A; Strano A; Pifarre R
Pharmacological modulation of fibrinolysis by antithrombotic and cardiovascular drugs.
Progress in cardiovascular diseases 1992;34(6):379-98.
1992: Walenga J M; Hoppensteadt D; Fareed J; Pifarré R
Hemostatic abnormalities in total artificial heart patients as detected by specific blood markers.
The Annals of thoracic surgery 1992;53(5):844-50.
1992: Bacher P; Welzel D; Iqbal O; Hoppensteadt D; Callas D; Walenga J M; Fareed J
The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model.
Thrombosis research 1992;66(2-3):151-8.
1991: Fareed J; Walenga J M; Leya F; Bacher P; Hoppensteadt D; Messmore H; Pifarre R
Some objective considerations for the use of heparins and recombinant hirudin in percutaneous transluminal coronary angioplasty.
Seminars in thrombosis and hemostasis 1991;17(4):455-70.
1991: Fareed J
Venous thromboprophylaxis in the 1990s: a perspective.
Seminars in thrombosis and hemostasis 1991;17(4):317-21.
1991: Fareed J; Walenga J M; Hoppensteadt D; Iyer L; Pifarre R
Neutralization of recombinant hirudin: some practical considerations.
Seminars in thrombosis and hemostasis 1991;17(2):137-44.
1991: Walenga J M; Hoppensteadt D; Koza M; Pifarre R; Fareed J
Comparative studies on various assays for the laboratory evaluation of r-hirudin.
Seminars in thrombosis and hemostasis 1991;17(2):103-12.
1991: Mathru M; Dries D J; Zecca A; Fareed J; Rooney M W; Rao T L
Effect of fast vs slow intralipid infusion on gas exchange, pulmonary hemodynamics, and prostaglandin metabolism.
Chest 1991;99(2):426-9.
1991: Walenga J M; Bakhos M; Messmore H L; Fareed J; Pifarre R
Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model.
The Annals of thoracic surgery 1991;51(2):271-7.
1991: Fareed J; Walenga J M; Iyer L; Hoppensteadt D; Pifarre R
An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1991;2(1):135-47.
1991: Walenga J M; Bakhos M; Messmore H L; Koza M; Wallock M; Orfei E; Fareed J; Pifarre R
Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1991;2(1):105-11.
1991: Hubbard T; Olivier T; Bacher P; Walenga J M; Galal H; Fareed J; Pifarre R
Use of recombinant hirudin to increase the patency rate of microanastomosis in a rabbit model.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1991;2(1):101-3.
1991: Hoppensteadt D A; Walenga J M; Fareed J
Effect of dermatan sulfate and heparan sulfate on platelet activity compared to heparin.
Seminars in thrombosis and hemostasis 1991;17 Suppl 1():60-4.
1991: Fareed J; Hoppensteadt D; Walenga J M; Ahsan A; Coyne E; Breddin H K
Molecular and functional heterogeneity in dermatan sulfate preparations.
Seminars in thrombosis and hemostasis 1991;17 Suppl 2():174-80.
1991: Hoppensteadt D; Walenga J M; Fareed J
Protamine sulfate neutralization of lactobionic acid amides.
Seminars in thrombosis and hemostasis 1991;17 Suppl 2():153-7.
1991: Fareed J; Coker S; Iqbal O; Hoppensteadt D; Walenga J M
Pharmacodynamics of a sulfated lactobionic acid amide-derived antithrombotic agent (Aprosulate) in primates.
Seminars in thrombosis and hemostasis 1991;17 Suppl 2():147-52.
1991: Fareed J; Walenga J M; Pifarre R; Hoppensteadt D; Koza M
Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin.
Haemostasis 1991;21 Suppl 1():64-72.
1991: Walenga J M; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Laboratory assays for the evaluation of recombinant hirudin.
Haemostasis 1991;21 Suppl 1():49-63.
1991: Walenga J M; Hoppensteadt D; Fareed J
Non-heparin glycosaminoglycan-derived drugs: a biochemical and pharmacologic perspective.
Seminars in thrombosis and hemostasis 1991;17 Suppl 2():137-42.
1991: Lorens S A; Guschwan M; Hata N; van de Kar L D; Walenga J M; Fareed J
Behavioral, endocrine, and neurochemical effects of sulfomucopolysaccharide treatment in the aged Fischer 344 male rat.
Seminars in thrombosis and hemostasis 1991;17 Suppl 2():164-73.
1991: Messmore H L; Griffin B; Koza M; Seghatchian J; Fareed J; Coyne E
Interaction of heparinoids with platelets: comparison with heparin and low molecular weight heparins.
Seminars in thrombosis and hemostasis 1991;17 Suppl 1():57-9.
1991: Fareed J; Walenga J M; Hoppensteadt D; Borris L C; Lassen M R
Experimental and clinical validation of the prophylactic antithrombotic effects of a low molecular weight heparin (enoxaparin).
Seminars in thrombosis and hemostasis 1991;17 Suppl 3():319-28.
1991: Walenga J M; Hoppensteadt D; Fareed J
Laboratory monitoring of the clinical effects of low molecular weight heparins.
Thrombosis research. Supplement 1991;14():49-62.
1990: Hoppensteadt D; Walenga J M; Fareed J
Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin.
Thrombosis research 1990;60(3):191-200.
1990: Reddy V B; Kowal-Vern A; Hoppensteadt D A; Kumar A; Walenga J M; Fareed J; Schumacher H R
Global and molecular hemostatic markers in acute myeloid leukemia.
American journal of clinical pathology 1990;94(4):397-403.
1990: Fareed J; Walenga J M; Lassen M; Borris L; Hoppensteadt D; Murphy R; Ahsan A; Weber S; Jorgensen L N; Hauch O
Pharmacologic profile of a low molecular weight heparin (enoxaparin): experimental and clinical validation of the prophylactic antithrombotic effects.
Acta chirurgica Scandinavica. Supplementum 1990;556():75-90.
1989: Fareed J; Walenga J M; Hoppensteadt D; Racanelli A; Coyne E
Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization.
Seminars in thrombosis and hemostasis 1989;15(4):440-63.
1989: Racanelli A; Hoppensteadt D A; Fareed J
In vitro protamine neutralization profiles of heparins differing in source and molecular weight.
Seminars in thrombosis and hemostasis 1989;15(4):386-9.
1989: Hoppensteadt D; Racanelli A; Walenga J M; Fareed J
Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin.
Seminars in thrombosis and hemostasis 1989;15(4):378-85.
1989: Walenga J M; Pifarre R; Hoppensteadt D A; Fareed J
Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations.
Seminars in thrombosis and hemostasis 1989;15(3):316-33.
1989: Fareed J; Walenga J M; Cornelli U
Antithrombotic drugs in pelvic surgery.
Seminars in thrombosis and hemostasis 1989;15(2):230-2.
1989: Fareed J; Walenga J M; Hoppensteadt D; Huan X; Nonn R
Biochemical and pharmacologic inequivalence of low molecular weight heparins.
Annals of the New York Academy of Sciences 1989;556():333-53.
1989: Messmore H L; Griffin B; Fareed J; Coyne E; Seghatchian J
In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets.
Annals of the New York Academy of Sciences 1989;556():217-32.
1988: Walenga J M; Petitou M; Samama M; Fareed J; Choay J
Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activity.
Thrombosis research 1988;52(6):553-63.
1988: Coyne E; Walenga J M; Fareed J
Aggregates in heparin.
Journal of pharmaceutical sciences 1988;77(9):818-20.
1988: Walenga J M; Bara L; Petitou M; Samama M; Fareed J; Choay J
The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity.
Thrombosis research 1988;51(1):23-33.
1988: Choate J J; Domenico D R; McGraw T P; Fareed J; Molnar Z; Schumacher H R
Diagnosis of acute megakaryoblastic leukemia by flow cytometry and immunoalkaline phosphatase techniques. Utilization of new monoclonal antibodies.
American journal of clinical pathology 1988;89(2):247-53.
1988: Emanuele R M; Racanelli A; Fareed J
Pharmacokinetics of heparins differing in mean molecular weight using a Xa amidolytic and Heptest clotting method.
Therapeutic drug monitoring 1988;10(2):153-9.
1988: Fareed J; Walenga J M; Racanelli A; Hoppensteadt D; Huan X; Messmore H L
Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins.
Haemostasis 1988;18 Suppl 3():33-47.
1988: Fareed J; Walenga J M; Hoppensteadt D; Huan X; Racanelli A
Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins.
Haemostasis 1988;18 Suppl 3():3-15.
1988: Fareed J; Walenga J M; Hoppensteadt D A; Kumar A; Ulutin O N; Cornelli U
Pharmacologic profiling of defibrotide in experimental models.
Seminars in thrombosis and hemostasis 1988;14 Suppl():27-37.
1987: Emanuele R M; Fareed J
The effect of molecular weight on the bioavailability of heparin.
Thrombosis research 1987;48(5):591-6.
1987: Fareed J
[Low molecular weight heparin fractions. Comparative preclinical study of various parameters]
Journal des maladies vasculaires 1987;12 Suppl B():59-63.
1985: Racanelli A; Fareed J; Walenga J M; Coyne E
Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments.
Seminars in thrombosis and hemostasis 1985;11(2):176-89.
1984: Fareed J; Moncada R; Messmore H L; Walenga J M; Hoppensteadt D; Wehrmacher W H
Molecular markers of contrast media-induced adverse reactions.
Seminars in thrombosis and hemostasis 1984;10(4):306-28.
1983: Fareed J; Bick R L; Squillaci G; Walenga J M; Bermes E W
Molecular markers of hemostatic disorders: implications in the diagnosis and therapeutic management of thrombotic and bleeding disorders.
Clinical chemistry 1983;29(9):1641-58.
1983: Fareed J; Messmore H L; Walenga J M; Bermes E W
Diagnostic efficacy of newer synthetic-substrates methods for assessing coagulation variables: a critical overview.
Clinical chemistry 1983;29(2):225-36.
1983: Fareed J; Messmore H L; Walenga J M; Bermes E W
Synthetic peptide substrates in hemostatic testing.
Critical reviews in clinical laboratory sciences 1983;19(2):71-134.
1982: Fareed J; Messmore H L; Walenga J M; Bermes E W; Bick R L
Laboratory evaluation of antithrombin III: a critical overview of currently available methods for antithrombin III measurements.
Seminars in thrombosis and hemostasis 1982;8(4):288-301.
1980: Fareed J; Messmore H L; Bermes E W
New perspectives in coagulation testing.
Clinical chemistry 1980;26(10):1380-91.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Jawed Fareed

Research Profile (preview)

Chemicals & Drugs

Procedures

Anatomy

Concepts & Ideas

Living Beings

Physiology

Disorders

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Jawed Fareed (preview)

All Publications